These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3948308)

  • 1. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.
    Dorr RT; Alberts DS; Soble M
    Cancer Chemother Pharmacol; 1986; 16(2):91-4. PubMed ID: 3948308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skin ulceration potential of paclitaxel in a mouse skin model in vivo.
    Dorr RT; Snead K; Liddil JD
    Cancer; 1996 Jul; 78(1):152-6. PubMed ID: 8646711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent skin ulcers in mice treated with DNA binding antitumor antibiotics.
    Soble MJ; Dorr RT; Plezia P; Breckenridge S
    Cancer Chemother Pharmacol; 1987; 20(1):33-6. PubMed ID: 3621451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor.
    MacDonald JR; Pegg DG
    Cancer Chemother Pharmacol; 1993; 32(5):365-7. PubMed ID: 8339386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidote studies of vinorelbine-induced skin ulceration in the mouse.
    Dorr RT; Bool KL
    Cancer Chemother Pharmacol; 1995; 36(4):290-2. PubMed ID: 7628047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradermal carboplatin and ifosfamide extravasation in the mouse.
    Marnocha RS; Hutson PR
    Cancer; 1992 Aug; 70(4):850-3. PubMed ID: 1643617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 1997; 9(5):249-57. PubMed ID: 9306432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental dacarbazine antitumor activity and skin toxicity in relation to light exposure and pharmacologic antidotes.
    Dorr RT; Alberts DS; Einspahr J; Mason-Liddil N; Soble M
    Cancer Treat Rep; 1987 Mar; 71(3):267-72. PubMed ID: 3815394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.
    Jin G; You Y; Ahn B
    Bioorg Med Chem Lett; 2001 Jun; 11(11):1473-6. PubMed ID: 11378380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.
    Coltman CA; Coltman TM; Balcerzak SP; Morrison FS; Von Hoff DD
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):50-3. PubMed ID: 6484581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment methods for extravasations of chemotherapeutic agents: a comparative study.
    Loth TS; Eversmann WW
    J Hand Surg Am; 1986 May; 11(3):388-96. PubMed ID: 3711613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between subcutaneous steroid injection for extravasation of vesicant anticancer drugs and skin ulcers requiring surgery.
    Ohisa K; Yamana H; Morita K; Matsui H; Fushimi K; Yasunaga H
    Eur J Oncol Nurs; 2022 Jun; 58():102119. PubMed ID: 35358899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extravasation of dactinomycin, vincristine, and cisplatin: studies in an animal model.
    Buchanan GR; Buchsbaum HJ; O'Banion K; Gojer B
    Med Pediatr Oncol; 1985; 13(6):375-80. PubMed ID: 4046975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety assessment of new anticancer compound, mitoxantrone, in beagle dogs: comparison with doxorubicin. II. Histologic and ultrastructural pathology.
    Sparano BM; Gordon G; Hall C; Iatropoulos MJ; Noble JF
    Cancer Treat Rep; 1982 May; 66(5):1145-58. PubMed ID: 7083217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DNA repair in cells treated with a combination of alkylating agents.
    Frankfurt OS; Seckinger D; Sugarbaker EV
    Anticancer Res; 1993; 13(4):947-52. PubMed ID: 8352564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic and biochemical effects of mitoxantrone.
    Durr FE
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):3-10. PubMed ID: 6484579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
    Ayash L; Korbut T; Herman TS; Teicher BA
    Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone in malignant lymphoma.
    Gams RA; Steinberg J; Posner L
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):47-9. PubMed ID: 6484580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study.
    Smyth JF; Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):15-8. PubMed ID: 6484578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.